About this Research Topic
This research topic aims to discuss novel evidence and summarize existing data on the genetics and epigenetics of both melanoma and non-melanoma skin cancers. The primary objectives include exploring the genetic and epigenetic impacts on the treatment of these cutaneous disorders, advancing pharmacogenomics, and implementing genetic and epigenetic diagnostics in clinical practice. Specific questions to be addressed include the identification of novel pathogenic variants, the role of epigenetic modifications in disease progression, and the potential of new technologies such as single-cell and high-throughput omics to uncover molecular mechanisms and therapeutic targets.
To gather further insights into the genetics and epigenetics of melanoma and non-melanoma skin cancers, we welcome articles addressing, but not limited to, the following themes:
• Diagnostic yield of next-generation sequencing in patients with melanoma and non-melanoma skin cancer.
• Identification of novel genes/pathogenic variants involved in these skin disorders, including exome/whole genome sequencing and single nucleotide peptide (SNP)-based approaches.
• Implementation of genetic tools in clinical dermatological practice.
• State-of-the-art and novel insights into the epigenetic landscape underlying melanoma and non-melanoma skin cancers.
• Artificial intelligence, machine learning, and deep learning approaches for skin cancer detection.
Bioinformatic studies are welcome, provided they include an independent validation cohort for statistically significant confirmation of the findings communicated.
Keywords: Genetics, DNA sequencing, Next-generation sequencing, Genome-wide association study, Epigenetics, Melanoma skin cancer, Non-melanoma skin cancer, Health outcomes, Precision medicine, Molecular Dynamics, drug discovery, Artificial Intelligence
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.